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Abstract 
Purpose: 
A survey of quality control (QC) currently undertaken in UK radiotherapy centres for 
high  dose  rate  (HDR)  and  pulsed  dose  rate  (PDR)  brachytherapy  has  been 
conducted.  The  purpose  was  to  benchmark  current  accepted  practice  of  tests, 
frequencies and tolerances to assure acceptable HDR/PDR equipment performance. 
It is 20 years since a similar survey was conducted in the UK and the current review 
is  timed to  coincide with  a revision of  the IPEM Report  81 guidelines for  quality 
control in radiotherapy. 
Material and Methods: 
All  radiotherapy  centres  in  the  UK  were  invited  by  email  to  complete  a 
comprehensive questionnaire on their current brachytherapy QC practice, including: 
equipment type, patient workload, source calibration method, level of image guidance 
for  planning,  prescribing  practices,  QC  tests,  method  used,  staff  involved,  test  
frequencies, and acceptable tolerance limits.
Results: 
Survey data was acquired between June and August 2012. Of the 64 centres invited,  
47 (73%) responded, with 31 centres having brachytherapy equipment (3 PDR) and 
fully  completing  the  survey,  13  reporting  no  HDR/PDR  brachytherapy,  and  3 
intending  to  commence  HDR  brachytherapy  in  the  near  future.  All  centres  had 
comprehensive QC schedules in place and there was general agreement on key test 
frequencies  and  tolerances.  Greatest  discord  was  whether  source  strength  for 
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treatment planning should be derived from measurement, as at 58% of centres, or 
from the certified value, at 42%.  IPEM Report 81 continues to be the most frequently 
cited source of QC guidance, followed by ESTRO Booklet No.8. 
Conclusions: 
A comprehensive survey of QC practices for HDR/PDR brachytherapy in UK has 
been conducted. This is a useful reference to which centres may benchmark their 
own practice. However individuals should take a risk-assessment based approach, 
employing full knowledge of local equipment, clinical procedures and available test  
equipment in order to determine individual QC needs.  
Keywords: 
High dose rate (HDR); brachytherapy; quality control (QC); quality assurance (QA); 
survey.
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Main Body Text
Purpose
The  dosimetric  accuracy  of  brachytherapy  delivery  is  fundamental  to  the 
achievement of clinical treatment aims, tumour control and minimised normal tissue 
toxicity. As early as 1993 Van Dyk et al. [1] defined a requirement for brachytherapy 
treatment delivery of 3% accuracy in dose at distances of 0.5 cm or more at any point  
for any radiation source. Control of dose delivery is particularly difficult to achieve in 
brachytherapy due to  small  treatment  distances,  very  high  dose gradients  and a 
multitude  of  aspects  that  affect  accuracy  [2].  A  quality  assurance  system  in 
radiotherapy is essential to ensure treatment delivery is consistent and as intended. 
This will include a multitude of quality control (QC) tests designed to evaluate actual 
operating  performance  in  comparison  to  goal  values,  and  to  enable  rectification/ 
reconciliation of any differences. 
Brachytherapy is currently undergoing a period of significant innovation and rapid 
modernisation [3], including a shift  from 2D to 3D basis [4], the enhanced use of 
imaging  [5],  patient-specific  treatment  plan  optimisation,  fully  volume-based 
prescribing  [6],  inverse-planning  [7],  advanced  planning  algorithms  [8],  use  of 
advanced treatment applicators [9,  10],  and in-vivo dosimetry verification systems 
[11]. It is essential that QC test schedules keep pace with the changing technology 
and clinical practice. This includes re-assessing the use of historic QC tests that are 
no longer  fit  for  purpose and replacing with  more relevant  QC,  or  where  system 
performance is verified by other means avoiding unnecessary redundancy.
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Quality assurance of all brachytherapy techniques has recently received increased 
attention following low dose rate brachytherapy incident in 2009 at the Philadelphia 
VA Medical Centre in which a number of patients received poor quality prostate seed 
brachytherapy treatment [12]. There have also been errors in brachytherapy due to 
confusion of source strength units, including incorrect entry into treatment planning 
systems  [13].  In  addition,  there  are  numerous  publications  on  more  subtle 
equipment-related  quality  issues  in  high  dose  rate  (HDR) delivery,  such  as 
unexpected, irregular spacing of source dwell positions in ring applicators [14]. It is  
important  that  QC testing  is  robust  and comprehensive  and meets  the  needs of 
modern equipment and treatment techniques.
It is over twenty years since a comprehensive assessment has been undertaken of 
brachytherapy QC practice in the United Kingdom (UK): reproduced in the Institute of 
Physics and Engineering in Medicine (IPEM) Report 81 [15]. The IPEM guidance on 
QC for radiotherapy is currently being revised, and it is therefore timely to undertake 
a repeat benchmark exercise of current QC practice for brachytherapy. The present 
survey has been endorsed by the  IPEM Radiotherapy Special  Interest  Group.  A 
similar survey was conducted in 2002 in the Netherlands and Belgium [16] which 
reported large variations in test frequencies and methods, and differences in QC-
philosophy and available equipment. The authors are unaware of any contemporary 
comparisons of brachytherapy QC practice.
The publication of a comprehensive assessment of current QC practice has several 
potential benefits for individual radiotherapy departments: centres may be reassured 
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that their QC systems are in-line with accepted practice; alternatively, centres may 
identify discrepancies against standards of practice. Following investigation, this may 
lead  to  either  reduction  of  tests  or  frequencies  and hence efficiency savings,  or 
resolution of deficiencies and potential improvements in safety and quality. However, 
the details of QC tests presented here should not be interpreted as guidelines or  
recommendations, but as a ‘snapshot’ of current UK practice. It is important to be 
aware that specific QC testing is a local decision, based on many local factors, and 
should ideally be based on risk-assessment approaches.
Materials and Methods 
All  64  radiotherapy centres  in  the  UK were  contacted by  email  in  June 2012 to 
request their contribution to the study, with collation of responses taking place during 
June to August 2012. Centres were asked to complete a detailed questionnaire on 
their routine QC practices and other aspects of HDR and PDR service provision.  To 
enable a contextual  review of  QC practice,  initial  questions were  asked included 
equipment type, average patient workload, sites treated, source strength calibration 
methods,  level  of  image  guidance,  and  prescribing  practice.  A  spreadsheet 
containing a comprehensive list  of possible quality control  tests for treatment and 
planning equipment was also provided. Centres were asked to document whether 
they routinely perform each test, at what frequency, by which staff group, and the 
acceptable tolerance values used. They were also asked to comment whether the 
target test frequencies were actually achieved in practice.
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Results 
Equipment profile and general physics aspects of brachytherapy service
47 (73%) of the 64 UK radiotherapy centres that were invited to take part  in the 
survey of HDR and PDR QC responded. 31 centres had appropriate brachytherapy 
equipment  and provided  fully  completed questionnaires  on their  QC practice.  13 
centres reported no HDR or PDR brachytherapy facilities, and a further 3 intended to 
commence HDR brachytherapy in the near future.
The majority  (29)  of  radiotherapy centres  had HDR units,  with  only  three having 
access to PDR treatments, two having exclusively PDR. The equipment profile of the 
responding  centres  included  20  Nucletron/Elekta  microSelectron,  7  Varian 
GammaMed, 4 Nucletron/Elekta/Isodose Control Flexitron, 1 Eckert & Ziegler Bebig 
HDR Multisource, and 1 Varian Varisource. One centre had 3 treatment units, 1 HDR 
and 2 PDR, all others had 1 unit. One centre had a Co-60 source (HDR), the others 
were all using Ir-192. The latter isotope being exchanged at 3-monthly intervals in all 
but two centres: one at 4-monthly intervals and another PDR centre at between 3 
and  6  months.  One  centre  stated  they  were  considering  moving  to  4-monthly 
intervals to reduce cost. The planned frequency of exchange for the Co-60 source 
was 4 years. The mean number of HDR fractions delivered per year at each centre 
was 281, with interquartile range 173 to 359 (minimum 80 and maximum 730). 
7
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
There was a lack of agreement as to  whether  the locally measured value or the 
manufacturer’s supplied source certificate should be used for the source strength 
value in treatment planning calculations; 18 centres (58%) preferring to use their own 
measurement. The current UK Code of Practice for HDR brachytherapy dosimetry [5] 
recommends  a  well  chamber  for  the  primary  source  strength  measurement,  but 
allows  some  flexibility  in  the  method  used  to  obtain  the  second  independent 
verification value. Table 1 lists methods used for source calibration and their relative 
popularity within UK centres.
The  quoted  origin  of  the  TG-43  [18]  source  model  data  used  in  the  treatment 
planning  systems  also  varied  between  centres.  14  (45%)  used  the  supplied 
manufacturer  data,  8  (26%)  used  journal  published  data,  and  8  (26%)  used 
manufacturer data and verified this against publications, (with 1 (3%) not answering 
the question). There was also a variety of methods quoted as an independent check 
of the output of the treatment planning system. The methods and their popularity are 
given in Table 2.
Treatment plan optimisation in some form was used in 23 centres (73%), including 
for cervix (majority), prostate (next most common), skin/limb moulds, interstitial anus, 
vaginal vault,  lung, head & neck, multilumen mammosite breast,  intraluminal,  and 
keloid scars. 27 centres (87%) optimised treatment plans for individual patients; 19 
(61%)  employing  manual  methods  and  the  others  inverse  planning  optimisation, 
often with final manual adjustment. 6 centres (19%) stated they used pre-optimised 
standard plan libraries.
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The  level  of  image-guidance  varied  significantly  between  centres.  In  cervix 
treatments, 16 (52%) used CT alone for treatment planning, 12 (39%) MRI with CT, 2 
(6%) MRI alone, and 1 (3%) c-arm 2D imaging alone. When MRI was available this 
was often used for the first  fraction, with  CT used in subsequent treatments.  For 
vaginal vault treatments, 13 (42%) did not image, 10 (32%) used orthogonal 2D x-
ray, and 8 (26%) used CT. Some centres responded they would only image vault  
treatments for complex cases or if individualised plans were required. There were an 
insufficient  number  of  responses  on  imaging  used  for  other  treatment  sites  for 
statistical significance.
Gynaecology cancers were the most commonly treated. In cervix, 22 centres (71%) 
still prescribe treatment doses to Manchester Point A. For those prescribing instead 
to high-risk clinical target volume, HR-CTV [19], all  centres additionally record the 
Point A dose. Only 2 centres (6%) exclusively recorded ICRU organ at risk (OAR) 
point doses, likely when only orthogonal imaging is used, the others recorded either 
just  GEC-ESTRO dose-volume histogram (DVH) data  (48%),  or  both ICRU point 
dose and DVH data (46%). 
Centres were asked to list the primary sources of guidance used in establishing their 
HDR or PDR quality control schedules. Table 3 provides a list of the documents that 
were indicated and their popularity, quoted as the percentage of centres citing the 
document. All centres stated they had reviewed the content of their HDR/PDR QC 
schedule within the last two years, except two which did not answer the question.
Quality Control tests
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Table 4 provides detail  from the HDR and PDR QC survey.  The table shows the 
percentage of centres that  include each of the specific tests  in their  planned QC 
schedules. A centre is deemed to have included the test in their regular QC if it is  
performed  within  the  department  whether  it  is  in  the  specific  ‘physics  QC 
documentation’  or  other  ‘standard  operating  procedures’,  for  plan  checking  for 
example. A test is deemed not to be in regular QC if  it  was only intended to be 
performed  once  at  initial  equipment  commissioning.  The  mean  and  range  of 
frequencies  of  testing  and  acceptable  tolerance  levels  are  provided  in  the  table. 
There is a significant variation in consistency between centres across the range of 
tests. Inclusion of tests in QC schedules varies from 31 centres (100%) for source 
strength measurements to just 2 centres (6%) for MRI tests, the latter of course being 
due to limitations of access to MRI for brachytherapy-specific clinical use and QC 
testing. (It was not recorded how many centres routinely used MRI for brachytherapy 
planning). The consistency of frequency of testing and acceptable tolerance levels 
also varies markedly between the individual QC tests, between complete or lack of 
agreement  for  specific  tests.  Of  the  45  tests  included  in  the  survey,  21  were 
performed at greater than 75% of centres, and 4 were performed at less than 25% of 
centres. There were no significant differences in the QC techniques employed for 
HDR  and  PDR  equipment,  and  certainly  within  the  range  of  practice  between 
centres.  Only  2  centres  (6%)  reported  achieved  measurement  frequencies  were 
below planned measurement frequencies, and then only for up to two tests each..
Table  5  documents  additional  QC tests  suggested  by  responding centres,  which 
were not  included in the original  list  of  tests in the distributed survey.  These are 
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generally  proposals  made  by  single  centres  and  there  is  no  information  of  the 
popularity of these tests across UK, however they are included for interest.
Quality control testing of dosimetry equipment associated with HDR and PDR use 
has not  been included in  the results  tables;  secondary standard calibrations  and 
consistency testing of well  chambers and Farmer-type ionisation chambers, which 
are covered elsewhere and in published codes of practice [17]. 
Discussion
The  survey  data  presented  in  this  report  represents  the  current  practice  in  the 
majority  of  brachytherapy  centres  within  the  UK.  Whilst  there  is  a  high  level  of 
consistency in  inclusion,  frequency and tolerance values for  some tests,  such as 
source strength measurement, there are varied responses to other tests. This is likely 
due  to  differences  in  local  planning  and  treatment  procedures  in  clinical  use, 
availability  of  equipment,  and differing  functionality  or  performance of  equipment. 
Local assessment of QC needs is essential in determining schedules, rather than 
simple  reliance  on  the  ‘majority  view’.  However,  benchmarking  against  accepted 
practice  is  a  good  starting  point  for  local  review.  A  risk  assessment  approach 
including  local  known  factors  is  advocated  for  final  decisions on QC testing.  All 
schedules must include measurement of source strength, source position and 
dwell time, but the specific details require knowledge of local clinical practice 
and equipment in use.
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While  there  was  some variation  in  staff  groups  involved  in  QC testing  between 
centres, physics staff most commonly performed all of the QC tests except facilities 
testing (table 4) which was almost exclusively performed by radiographers. Within 
each centre, a specific QC test may be performed in multiple ways, including staff  
group involved, equipment used, frequency of measurement, and tolerance value. 
Each  different  measurement  method  has  been  included  in  the  results  table.  For 
example, ‘decay correction accuracy at treatment unit’  may be performed prior to 
each patient  treatment  by radiographers,  and separately  by radiotherapy physics 
after  each  source  change  but  to  a  tighter  investigation  tolerance  level.  The 
achievable tolerance value for this test is also dependent on the equipment design, 
whether  the software  makes hourly corrections for  source decay or  12-hourly for 
example. The standard operating procedures of individual departments also have a 
significant affect on the QC testing that is performed. This includes all aspects such 
as  whether  optimised  or  standard/tabulated  planning is  used,  whether  2D or  3D 
imaging  is  utilised,  and  whether  electronic  transfer  of  data  is  available.  An 
independent method for the verification of the accuracy of treatment plans is required 
for individually-optimised treatments, but may not be required for each patient if a  
standard  plan  is  used  that  has  previously  been  verified  and  is  checked  for 
consistency.
Some tests are adopted by all centres such as ‘source strength measurement’ and 
‘source position in a straight catheter’.  However  others such as ‘x-ray imaging of 
applicators’ is undertaken by only 32% of centres. The difference may be attributed 
to whether the process is already being assessed by alternative means, and there is 
some  evidence  from  the  survey  to  support  this.  For  applicator  dimensions  and 
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angles, a specific measurement may not be necessary if the consistency of shape is 
evaluated through agreement to planning system library applicators used for each 
individually-planned  treatment  (provided  both  physical  applicator  and  library 
applicator have already been tested at commissioning).  Checking of the 1st dwell 
position should however be verified in this case.
The  number  of  centres  including  a  routine  measurement  of  actual  source  dwell 
positions  in  clinical  applicators  was  surprisingly  low,  at  17  centres  (55%).  Such 
testing should be performed at commissioning and at regular intervals, particularly if  
ring applicators are in  use, in  which the actual  and TPS planned dwell  positions 
should be compared. 
IPEM Report 81 [21] was the most frequently cited document used for guidance 
on required HDR or PDR QC tests, but  it  is surprising that only 61% of UK 
centres  cited  this  document,  being  the  UK  professional  body’s 
recommendations for QC. This  may be because the document is now quite 
dated. More recent, but again surprisingly cited by only 48% of centres is the 
ESTRO Booklet No. 8 [22]. There is a large range in the documents identified 
by  individual  centres  as  their  primary  sources  of  guidance  for  QC testing, 
supporting the need for an update of IPEM Report 81 in UK.
Conclusions
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A  benchmark  data  set  of  brachytherapy  HDR  and  PDR  QC  testing  has  been 
presented which is representative of practice across the UK. This updates a previous 
survey conducted over twenty years ago. 
A modern approach to QC is required to ensure continued safety and highest quality 
brachytherapy into the future as technology and procedures continue to increase in 
complexity, alongside increasing workforce pressures. QC testing schedules must be 
designed intelligently including risk-based assessments of need rather than simply 
maintaining historic tests. 
The contents of this report should not be interpreted as professional advice as to the 
requirements of a brachytherapy QC schedule and are presented as a benchmark 
data set. Local decisions on QC testing must be made based on full risk-assessment 
and local factors.
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Table Legends
Table 1. Methods employed, and their popularity, for source strength measurement 
of HDR & PDR sources at centres in UK
Table 2. Methods employed, and their popularity, to independently verify treatment 
planning system (TPS) calculations at centres in UK
Table  3. Primary  sources  of  guidance  for  establishing  QC  schedules,  and  their 
popularity at centres in UK
Table  4.  HDR & PDR QC survey:  Response to  questionnaire on test  popularity, 
measurement frequency and tolerance values 
Table 5. HDR & PDR QC survey: Additional tests identified by responding centres, 
not included in original survey questionnaire 
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Table 1.
Technique for determination of source strength Number of centres
Percentage 
of centres
Initial 
method
• Well chamber 29 94%
• Manufacturer supplied source certificate 1 3%
• NE2571 chamber with in-air jig 1 3%
Verification 
method
• Well chamber (second unit) 14 45%
• NE2571 chamber with in-air jig 12 39%
• NE2571 chamber in solid phantom 2 6%
• Manufacturer supplied source certificate 1 3%
• I-125 seed device with adaptor 1 3%
• Gafchromic film calibrated via 260kV x-rays 1 3%
1
Table 2.
Technique for verification of TPS calculation Number of centres
Percentage 
of centres
• Locally developed check software (including systems based on Matlab, Excel, 
Java, visual basic; usually employing either TG43 [18] or BIR/IPSM 1993 [20]. 16 52%
• Commercial check software or additional TPS (including IMSure QA, 
Radcalcbrachy, Lifeline) 7 23%
• Manual calculation or use of data tables 3 10%
• Nomogram (prostate treatment) or TRAK relationship to target volume 2 6%
• Use of standard plans only with initial independent calculation, no per-patient 
plan verification 2 6%
• Consistency check performed with standard plan on same day 1 3%
1
Table 3. 
Documents providing guidance on HDR or PDR QC
Number of 
centres citing 
document
Percentage of 
centres citing 
document
• Physics aspects of quality control in radiotherapy, IPEM Report 81 [21] 19 61%
• A practical guide to quality control of brachytherapy equipment, ESTRO 
Booklet No. 8 [22] 15 48%
• The IPEM code of practice for the determination of the reference air kerma rate 
for HDR (192)Ir brachytherapy sources based on the NPL air kerma standard, 2010 
[17]
10 32%
• Code of practice for brachytherapy physics, AAPM TG-56, 1997 [23] 8 26%
• Discussion with colleagues and other centres’ documents 6 19%
• High dose-rate brachytherapy treatment delivery, AAPM TG-59, 1998 [24] 4 13%
• Recommendations for Brachytherapy Dosimetry, BIR/IPSM Report 1993 [20] 3 10%
• Calibration of photon and beta ray sources used in brachytherapy, IAEA 
TecDoc 1274, 2002 [25] 3 10%
• Quality assurance for clinical radiotherapy treatment planning, AAPM TG-53, 
1998 [26] 2 6%
• Quality assurance tests for prostate brachytherapy ultrasound systems,  AAPM 
TG-128, 2008 [27] 2 6%
• Manufacturer’s guidance or manual 2 6%
• A revised AAPM protocol for brachytherapy dose calculations,  AAPM TG-
43U1, 2004 [18] 2 6%
• Thomadsen BR ‘Achieving quality in brachytherapy’, 1999 [28] 2 6%
• Other radiotherapy or brachytherapy text books, each n=1 2 6%
• Remote afterloading technology, AAPM TG-41, 1993 [29] 1 3%
• Towards Safer Radiotherapy, joint report of RCR, SoR, CoR, IPEM, NPSA, 
BIR, 2008 [30] 1 3%
• In-house experience with treatment unit 1 3%
• Quoted “Relevant regulations” 1 3%
• Quoted “Unsure of origin” 1 3% 
1
Table 4.
QC test
% of 
centres 
including 
in 
routine 
QC
Measurement intervals
% using mean value 
(and range of 
responses)
Tolerance
% using mean value 
(and range of 
responses)
Comments
S
ou
rc
e 
st
re
ng
th
• Initial measurement 
after source installation 100%
100% at source change
(all centres)
52% use 3%
(2% to 5%)
Achievable 
tolerance 
depends on test 
method and 
whether result is 
compared to 
certificate or 1st 
measurement
• Independent 
measurement after source 
installation
100%
100% at source change
(all centres)
35% use 3%
(0.5% to 5%)
• Repeat measurements 
during life of source 75%
83% at 1m
(1 d to 1m)
56% use 3%
(0.5% to 5%)
• Leak testing of source 97%
97% at source change
(1m to source change)
71% not > 
background
(zero to 200 Bq)
T
re
at
m
en
t u
ni
t f
un
ct
io
n
• Confirm accuracy of 
source data at treatment unit 97%
41% at each patient
(each patient to 
commissioning only)
55% use exact match
(exact to 4%)
• Confirm accuracy of 
decay correction at treatment 
unit for plans
91%
86% at each patient
(weekly to 
commissioning only
22% use 1%
(exact match to 3%)
Tolerance 
depends on how 
frequently unit 
makes decay 
correction
• Plan data transfer from 
TPS 83%
96% at each patient
(weekly to 
commissioning only)
63% use exact match
(0.1 s to 2%)
Some standard 
template plans 
not electronically 
transferred
• Simulated treatment 
functionality test 68%
68% at 1d
(1d to 12m)
50% use 1mm
(1 mm to 2 mm)
May be 
independent test 
or combined
• System display and 
print-out accurate and in 
agreement
96%
83% at each patient
(each patient to 
commissioning only)
88% use exact match
(exact to 2%)
• Test of function with 
mains power loss 58%
50% at 3m
(1m to 12m) 
• Test of uninterruptable 
power supply (UPS) 44%
31% at 3m
(1d to 12m)
d = day, w = week, m = month, y = year, TPS = treatment planning system
…table continues on next page.
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QC test
% of 
centres 
including 
in 
routine 
QC
Measurement intervals
% using mean value 
(and range of 
responses)
Tolerance
% using mean value 
(and range of 
responses)
Comments
A
pp
lic
at
or
s,
 s
ou
rc
e 
po
si
tio
n 
an
d 
so
ur
ce
 m
ov
em
en
t
• Visual inspection of 
applicators and transfer tubes 
for damage
97%
70% at 1d
(1d to 12m)
• Measurement of 
dimensions and angles of 
applicators and transfer tubes
48%
46% at commissioning
(each patient to 12m)
75% use 1 mm
(0.5 mm to 1 mm)
Often rely on 
image match to 
TPS library
• X-ray imaging of 
applicators 32%
64% at commissioning
(3m to 12m)
100% use 1 mm
Most commonly 
only when 
suspected 
damage 
• Verification of source 
dwell timer accuracy 97%
38% at 1d
(1d to 12m)
38% use 1s
(0.1 s to 2 s)
Large variation 
in definition of 
test 
methodology 
• Measurement of source 
dwell positions in straight 
catheter (not clinical applicator)
100%
42% at 1d
(1d to 4m)
78% use 1 mm
(0.5 mm to 2 mm)
Multiple 
techniques often 
in use at each 
centre 
• Measurement of source 
dwell positions in clinical 
applicators
55%
36% at commissioning
(2w to 12m)
79% use 1 mm
(1 mm to 2 mm)
• Measurement of actual 
source dwell positions 
compared to TPS stated 
position in complex geometry 
e.g. ring applicator
41%
35% at 3m
(2w to commissioning)
67% use 1 mm
(1 mm to 3 mm)
Absence of test 
often due to ring 
applicator not 
being used
• Source position relative 
to dummy source or marker wire 60%
35% at commissioning
(1d to 12m)
72% use 1 mm
(0.5 mm to 2 mm)
Absence of test 
normally due to 
marker wire not 
being used
• Applicator/transfer tube 
connection interlock and 
simulated error
73%
68% at 1d
(1d to 6m)
• Verification of expected 
position of internal applicator 
shielding
15%
50% at each patient
(each patient to 
commissioning)
Not commonly in 
use in UK
• Measurement of source 
transit times 47%
41% at 3m
(1w to commissioning)
No consistency, 
responses were: 
0.1 s, < 0.5 s,  <1 s, 
not > baseline, not > 
0.05 s dwell equivalent 
Large variety of 
techniques (well 
chamber to stop 
watch) and 
tolerance values
• Confirm error code 
‘meanings and actions’ are 
available at treatment unit
36%
25% each at 1d and 
12m 
(1d to commissioning)
Historic test, 
mostly replaced 
with improved 
software 
interface 
information
• Radiation monitor of 
applicators after use 26%
86% at each patient
(each patient to 1w)
100% not above 
background
Majority rely on 
in-room radiation 
monitor
d = day, w = week, m = month, y = year, TPS = treatment planning system
2
…table continues on next page.
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QC test
% of 
centres 
including 
in 
routine 
QC
Measurement intervals
% using mean value 
(and range of 
responses)
Tolerance
% using mean value 
(and range of 
responses)
Comments
T
re
at
m
en
t p
la
nn
in
g 
sy
st
em
• Accuracy of source 
model data used by TPS (e.g. 
check TG-43 data against 
reference values)
36%
65% at commissioning
(1m to commissioning)
No consistency
(Interpolation to 5%)
Normally 
undertaken at 
software 
updates
• Accuracy of individual 
source data used by TPS (e.g. 
source strength, calibration 
date)
89%
64% at each patient
(each patient to 3m)
No consistency, 
responses were: 
exact match, rounding 
error, 1 day correction, 
0.5%, 1%, 2%, 3%.
Tolerance may 
depend on how 
frequently unit 
makes decay 
correction
• Calculation of standard 
plans compared to reference 
data
63%
28% at 3m
(1d to commissioning)
No consistency, 
responses were: 
exact match, 1%, 2%, 
3%, 5%, 1 mm 
idsodose lines
• Independent check 
calculation of TPS patient plans 
or standard plans.
62%
74% at each patient
(each patient to 
commissioning)
50% use 3%
(1% to 5%)
Depends 
whether patient-
specific 
optimised or 
standard plans 
are in use
• Repeat of tests 
performed at TPS 
commissioning (e.g. DVH 
accuracy, geometric tests)
32%
39% at 3m
(1m to commissioning)
33% use 2 mm
(variety of definitions 
including mm, % of 
DVH or dose points)
Often performed 
at software 
updates only
Im
ag
in
g
• 2D kV imaging tests, 
including applicator 
reconstruction
24%
29% at 1d
(1d to commissioniong)
50% use 2%
(1% to 2%, or 2 mm)
Absence of test 
often due to 2D 
imaging not 
being used
• CT imaging tests, 
including applicator 
reconstruction
38%
50% at commissioning 
(each patient to 
commissioning)
No consistency, 
responses were: 
1%, 2%, 3%, 5%, 
1 mm, 2 mm
Absence of 
specific tests 
often due to 
reliance on TPS 
applicator library
• MR imaging tests, 
including applicator 
reconstruction and distortion
6%
60% at commissioning
(3m to commissioning)
50% use 2 mm
(1 mm to 2 mm)
Absence of test 
often due to 
brachytherapy-
specific MR 
imaging not 
being used. 
Access to MR 
for QC often a 
problem.
• Ultrasound imaging 
tests, including applicator 
reconstruction and grid 
alignment
26%
43% at 3m
(1m to commissioning)
No consistency, 
responses were: 
1 mm, 2 mm, 1 cc, 5%
Absence of test 
often due to 
ultrasound 
imaging not 
being used
• Accuracy of image data 
transfer to TPS 60%
27% at each patient
(each patient to 
commissioning)
43% use exact match
(exact to 2 mm, or 2%)
Image-based 
data only
d = day, w = week, m = month, y = year, TPS = treatment planning system
…table continues on next page.
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QC test
% of 
centres 
including 
in 
routine 
QC
Measurement intervals
% using mean value 
(and range of 
responses)
Tolerance
% using mean value 
(and range of 
responses)
Comments
In
-v
iv
o 
do
si
m
et
ry
• Availability of in-vivo 
dosimetry system for 
brachytherapy?
19%
Not in clinical 
use in the 
majority of 
centres. 
Included TLD, 
diode, MOSFET.
• Calibration of in-vivo 
dosimetry system
60% 
(of 
19%)
50% at 1m
(1m to ‘as required’)
100% use 5%
• Test of in-vivo 
measurement against 
expected/planned dose 
measured in phantom
60% 
(of 
19%)
50% each at 1w and 
12m 100% use 5%
F
ac
ili
tie
s
• Visual (CCTV) and 
audible (intercom) patient 
monitoring
100%
93% at 1d
(1d to 3m)
functional
• Radiation warning lights 100%
90% at 1d
(1d to 4m)
functional
• Independent radiation 
monitor (room monitor) 100%
83% at 1d
(1d to 4m)
functional
• Interlocks (e.g. door, 
timer delay) 100%
90% at 1d
(1d to 4m)
functional
• Emergency stop control 100%
81% at 1d
(1d to 4m)
functional
C
on
tin
ge
nc
ie
s
• Practice of simulated 
emergency (e.g. source stuck) 97%
46% at 12m
(1w to 12m)
• Presence of emergency 
equipment (e.g. source 
container, forceps, shield, 
monitor)
97%
91% at 1d
(1d to 12m)
• Review of 
responsibilities (e.g who 
removes applicator if source 
stuck)
84%
50% at 1d
(1d to 12m)
d = day, w = week, m = month, y = year, TPS = treatment planning system
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Table 5.
Additional possible QC tests not included in the survey
E
qu
ip
m
en
t p
er
fo
rm
an
ce
• Dwell time linearity
• Check behaviour if transfer tube loop/curvature too tight
• Treatment interruption behaviour
• Source drive motor operational (check audible indication of movement)
• Satisfactory performance of system self-test
P
D
R
• PDR pulse timing
• Check of nurses’ station and remote control panels
• Cathether integrity and connectivity to PDR unit
• Partial treatment completion
T
P
S
• Consistency of plans between software version
• Data security including backup (patient information, source data, system settings)
Im
ag
in
g • Image fusion CT/MR
• MR image scaling
R
ad
ia
tio
n 
pr
ot
ec
tio
n • Radiation monitoring of treatment unit (e.g. dose rate at 5cm or 1m)
• Radiation monitor empty treatment unit during source change
• Receipt and return of source paperwork
• Confirm controls in place for source security
O
th
er
• External audit of system quality control/performance
1
